{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:12:46Z","timestamp":1793301166250,"version":"4.5.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001785","name":"Flinders University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001785","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Clozapine is a unique medication with a potential role in the treatment of severe borderline personality disorder (BPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The review examines the effectiveness of clozapine as a medication for management for severe BPD with high risk of suicide, violence or imprisonment, and aims to help guide clinical practice in managing severe BPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A database search of the terms \u201cClozapine\u201d AND \u201cBPD\u201d; \u201cAntipsychotics\u201d AND \u201cBPD\u201d; \u201cClozapine\u201d AND \u201cBorderline Personality Disorder\u201d; and \u201cAntipsychotics\u201d AND \u201cBorderline Personality Disorder\u201d were performed in CINAHL, Cochrane Library, Embase, Medline, PsychINFO, PubMed, and Web of Science. Full-text articles of clinical clozapine use for BPD were included for review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 24 articles consisting of 1 randomised control trial, 10 non-controlled trials, and 13 case reports were identified. Most of the studies reported benefits from clozapine when used for severe BPD. Many of the studies focused on clozapine use in BPD patients at high risk of suicide. Results from these non-controlled and case reports support the use of clozapine in patients with severe BPD at high risk of suicide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There may be a role for clozapine in treating severe treatment refractory BPD, especially for those patients at high risk of suicide and frequent hospitalisations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00213-023-06431-6","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T08:02:05Z","timestamp":1691827325000},"page":"2015-2031","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A systematic review of the role of clozapine for severe borderline personality disorder"],"prefix":"10.1007","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6366-0661","authenticated-orcid":false,"given":"Joshua","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.L.","family":"Looi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry Kit Wa","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Bastiampillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"6431_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jad.2008.01.024","volume":"111","author":"PF Abraham","year":"2008","unstructured":"Abraham PF, Calabrese JR (2008) Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 111:21\u201330","journal-title":"J Affect Disord"},{"key":"6431_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJM199307153290303","volume":"329","author":"JMJ Alvir","year":"1993","unstructured":"Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis--incidence and risk factors in the United States. N Engl J Med 329:162\u2013167","journal-title":"N Engl J Med"},{"key":"6431_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.9758\/cpn.2016.14.2.226","volume":"14","author":"B Amamou","year":"2016","unstructured":"Amamou B, Salah WBH, Mhalla A, Benzarti N, Elloumi H, Zaafrane F, Gaha L (2016) Use of clozapine for borderline personality disorder: a case report. Clin Psychopharmacol Neurosci 14:226","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"6431_CR4","unstructured":"Australian Medical Handbook (2022) Clozapine. AMH https:\/\/amhonline.amh.net.au\/chapters\/psychotropic-drugs\/antipsychotics\/clozapine. Accessed 16 Oct 2022."},{"key":"6431_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/2045125314532488","volume":"4","author":"SE Argent","year":"2014","unstructured":"Argent SE, Hill SA (2014) The novel use of clozapine in an adolescent with borderline personality disorder. Ther Adv Psychopharmacol 4:149\u2013155","journal-title":"Ther Adv Psychopharmacol"},{"key":"6431_CR6","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, VA.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"9","key":"6431_CR7","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","volume":"177","author":"GA Keepers","year":"2020","unstructured":"Keepers GA, Fochtmann LF, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong S (2020) The american psychiatric association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177(9):868\u2013872. https:\/\/doi.org\/10.1176\/appi.ajp.2020.177901","journal-title":"Am J Psychiatry"},{"key":"6431_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0140-6736(14)61394-5","volume":"385","author":"AW Bateman","year":"2015","unstructured":"Bateman AW, Gunderson J, Mulder R (2015) Treatment of personality disorder. Lancet 385:735\u2013743","journal-title":"Lancet"},{"key":"6431_CR9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4088\/JCP.v59n0302","volume":"59","author":"F Benedetti","year":"1998","unstructured":"Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 59:103\u2013107","journal-title":"J Clin Psychiatry"},{"key":"6431_CR10","first-page":"139","volume":"26","author":"A Beri","year":"2014","unstructured":"Beri A, Boydell J (2014) Clozapine in borderline personality disorder: a review of the evidence. Ann Clin Psychiatry 26:139\u2013144","journal-title":"Ann Clin Psychiatry"},{"key":"6431_CR11","first-page":"13","volume":"9","author":"AB Biswas","year":"2006","unstructured":"Biswas AB, Gibbon S, Gangadharan S (2006) Clozapine in borderline personality disorder and intellectual disability: a case report of four-year outcome. Ment Health Asp Dev Disabil 9:13","journal-title":"Ment Health Asp Dev Disabil"},{"key":"6431_CR12","first-page":"94","volume":"11","author":"AB Biswas","year":"2008","unstructured":"Biswas AB, Hands O, White J (2008) Velocardiofacial syndrome in intellectual disability: borderline personality disorder behavioral phenotype and treatment with clozapine--a case report. Ment Health Asp Dev Disabil 11:94\u2013101","journal-title":"Ment Health Asp Dev Disabil"},{"key":"6431_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.euroneuro.2015.03.017","volume":"25","author":"R Bridler","year":"2015","unstructured":"Bridler R, H\u00e4berle A, M\u00fcller ST, Cattapan K, Grohmann R, Toto S, Kasper S, Greil W (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: a comparison with other psychiatric disorders. Eur Neuropsychopharmacol 25:763\u2013772","journal-title":"Eur Neuropsychopharmacol"},{"key":"6431_CR14","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/schbul\/sbaa145","volume":"47","author":"SKW Chan","year":"2021","unstructured":"Chan SKW, Chan HYV, Honer WG, Bastiampillai T, Suen YN, Yeung WS, Lam M, Lee WK, Ng RMK, Hui CLM (2021) Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12-year follow-up study of first-episode schizophrenia-spectrum disorders. Schizophr Bull 47:485\u2013494","journal-title":"Schizophr Bull"},{"key":"6431_CR15","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1521\/pedi.1995.9.1.76","volume":"9","author":"KR Chengappa","year":"1995","unstructured":"Chengappa KR, Baker RW, Sirri C (1995) The successful use of clozapine in ameliorating severe self mutilation in a patient with borderline personality disorder. J Pers Disord 9:76","journal-title":"J Pers Disord"},{"key":"6431_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.4088\/JCP.v60n0710","volume":"60","author":"KR Chengappa","year":"1999","unstructured":"Chengappa KR, Ebeling T, Kang JS, Levine J, Parepally H (1999) Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J Clin Psychiatry 60:477\u2013484","journal-title":"J Clin Psychiatry"},{"key":"6431_CR17","doi-asserted-by":"crossref","first-page":"204512532210908","DOI":"10.1177\/20451253221090832","volume":"12","author":"MJ Crawford","year":"2022","unstructured":"Crawford MJ, Leeson VC, Evans R, Barrett B, McQuaid A, Cheshire J, Sanatinia R, Lamph G, Sen P, Anagnostakis K (2022) The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial. Ther Advs Psychopharmacol 12:20451253221090832","journal-title":"Ther Advs Psychopharmacol"},{"key":"6431_CR18","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neubiorev.2020.06.017","volume":"116","author":"L Del Matto","year":"2020","unstructured":"Del Matto L, Muscas M, Murru A, Verdolini N, Anmella G, Fico G, Corponi F, Carvalho A, Samalin L, Carpiniello B (2020) Lithium and suicide prevention in mood disorders and in the general population: a systematic review. Neurosci Biobehav Rev 116:142\u2013153","journal-title":"Neurosci Biobehav Rev"},{"key":"6431_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40479-015-0035-8","volume":"3","author":"GL Dickens","year":"2016","unstructured":"Dickens GL, Frogley C, Mason F, Anagnostakis K, Picchioni MM (2016) Experiences of women in secure care who have been prescribed clozapine for borderline personality disorder. Borderline Personal Disord Emot Dysregulation 3:1\u20134","journal-title":"Borderline Personal Disord Emot Dysregulation"},{"key":"6431_CR20","doi-asserted-by":"publisher","unstructured":"Fajumi T, Manzoor M, Carpenter K (2012) Clozapine use in women with borderline personality disorder and co-morbid learning disability. J Learn Disabil Offending Behav 3(1):11. https:\/\/doi.org\/10.1108\/20420921211236717","DOI":"10.1108\/20420921211236717"},{"key":"6431_CR21","unstructured":"U.S. Food and Drug Administration (2021) Information on clozapine. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-clozapine. Accessed 16 Oct 2022"},{"key":"6431_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.eurpsy.2003.11.004","volume":"19","author":"MM Ferrerri","year":"2004","unstructured":"Ferrerri MM, Loze J-Y, Rouillon F, Limosin F (2004) Clozapine treatment of a borderline personality disorder with severe self-mutilating behaviours. Eur Psychiatry 19:177\u2013178","journal-title":"Eur Psychiatry"},{"key":"6431_CR23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/0010-440X(93)90065-C","volume":"34","author":"FR Frankenburg","year":"1993","unstructured":"Frankenburg FR, Zanarini MC (1993) Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 34:402\u2013405","journal-title":"Compr Psychiatry"},{"key":"6431_CR24","first-page":"125","volume":"25","author":"C Frogley","year":"2013","unstructured":"Frogley C, Anagnostakis K, Mitchell S, Mason F, Taylor D, Dickens G, Picchioni MM (2013) A case series of clozapine for borderline personality disorder. Ann Clin Psychiatry 25:125\u2013134","journal-title":"Ann Clin Psychiatry"},{"key":"6431_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1752-1947-7-223","volume":"7","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D (2013) The CARE guidelines: consensus-based clinical case reporting guideline development. J Med Case Reports 7:1\u20136","journal-title":"J Med Case Reports"},{"key":"6431_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40263-017-0425-0","volume":"31","author":"E Hancock-Johnson","year":"2017","unstructured":"Hancock-Johnson E, Griffiths C, Picchioni M (2017) A focused systematic review of pharmacological treatment for borderline personality disorder. CNS Drugs 31:345\u2013356","journal-title":"CNS Drugs"},{"key":"6431_CR27","doi-asserted-by":"publisher","first-page":"e053943","DOI":"10.1136\/bmjopen-2021-053943","volume":"12","author":"S Hardoon","year":"2022","unstructured":"Hardoon S, Hayes J, Viding E, McCrory E, Walters K, Osborn D (2022) Prescribing of antipsychotics among people with recorded personality disorder in primary care: a retrospective nationwide cohort study using The Health Improvement Network primary care database. Br Med J 12:e053943. https:\/\/doi.org\/10.1136\/bmjopen-2021-053943","journal-title":"Br Med J"},{"key":"6431_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3109\/13651501.2011.590211","volume":"15","author":"C Haw","year":"2011","unstructured":"Haw C, Stubbs J (2011) Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clin Pract 15:270\u2013274","journal-title":"Int J Psychiatry Clin Pract"},{"key":"6431_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.schres.2004.05.015","volume":"73","author":"J Hennen","year":"2005","unstructured":"Hennen J, Baldessarini RJ (2005) Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 73:139\u2013145","journal-title":"Schizophr Res"},{"key":"6431_CR30","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovi\u0107 J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Br Med J 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"Br Med J"},{"key":"6431_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00606409","volume":"11","author":"J Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1977","unstructured":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4 J, Alhava E, Olkinuora M, Palva I (1977) Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 11:193\u2013198","journal-title":"Eur J Clin Pharmacol"},{"key":"6431_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"6431_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/bs.apha.2017.09.009","volume":"82","author":"JY Khokhar","year":"2018","unstructured":"Khokhar JY, Henricks AM, Sullivan ED, Green AI (2018) Unique effects of clozapine: a pharmacological perspective. Adv Pharmacol 82:137\u201362","journal-title":"Adv Pharmacol"},{"key":"6431_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1108\/AMHID-02-2015-0009","volume":"9","author":"R Kiani","year":"2015","unstructured":"Kiani R, Biswas A, Devapriam J, Alexander RT, Kumar S, Andrews H, Tromans SJ (2015) Clozapine use in personality disorder and intellectual disabilities. Adv Ment Health Int Disabil 9:363\u2013370","journal-title":"Adv Ment Health Int Disabil"},{"key":"6431_CR35","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)16770-6","volume":"364","author":"K Lieb","year":"2004","unstructured":"Lieb K, Zanarini MC, Schmahl C, Linehan MM, Bohus M (2004) Borderline personality disorder. Lancet 364:453\u2013461","journal-title":"Lancet"},{"key":"6431_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007999709113338","volume":"14","author":"HY Meltzer","year":"1997","unstructured":"Meltzer HY (1997) Treatment-resistant schizophrenia-the role of clozapine. Curr Med Res Opin 14:1\u201320","journal-title":"Curr Med Res Opin"},{"key":"6431_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J (2003) Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 60:82\u201391","journal-title":"Arch Gen Psychiatry"},{"key":"6431_CR38","doi-asserted-by":"crossref","first-page":"18308","DOI":"10.4088\/JCP.v61n0713e","volume":"61","author":"DD Miller","year":"2000","unstructured":"Miller DD (2000) Review and management of clozapine side effects. J Clin Psychiatry 61:18308","journal-title":"J Clin Psychiatry"},{"key":"6431_CR39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group* P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"6431_CR40","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3371\/CSRP.4.1.4","volume":"4","author":"A Mortimer","year":"2010","unstructured":"Mortimer A, Singh P, Shepherd C, Puthiryackal J (2010) Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses 4:49\u201355","journal-title":"Clin Schizophr Relat Psychoses"},{"key":"6431_CR41","doi-asserted-by":"publisher","DOI":"10.1017\/S204579602200049X","volume":"31","author":"Z Nabi","year":"2022","unstructured":"Nabi Z, Stansfeld J, Pl\u00f6derl M, Wood L, Moncrieff J (2022) Effects of lithium on suicide and suicidal behaviour: a systematic review and meta-analysis of randomised trials. Epidemiol Psychiatr Sci 31:e65","journal-title":"Epidemiol Psychiatr Sci"},{"key":"6431_CR42","unstructured":"National Institute for Health and Care Excellence (2015). Personality disorders: borderline and antisocial: quality standard. NICE. https:\/\/www.nice.org.uk\/guidance\/qs88. Accessed 15 Sep 2022"},{"key":"6431_CR43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/JCP.0000000000000970","volume":"38","author":"J O'Leary","year":"2018","unstructured":"O'Leary J, Purcell A, Hynes C, Huet J, Romanos M, McWilliams S (2018) Clozapine for the management of suicidal behavior in borderline personality disorder complicated by a cancer diagnosis: a case report and review of the literature. J Clin Psychopharmacol 38:642\u2013644","journal-title":"J Clin Psychopharmacol"},{"key":"6431_CR44","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"6431_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10:1\u201311","journal-title":"Syst Rev"},{"key":"6431_CR46","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/YIC.0b013e32833e23ed","volume":"25","author":"JC Pascual","year":"2010","unstructured":"Pascual JC, Mart\u00edn-Blanco A, Soler J, Ferrer A, Tiana T, Alvarez E, P\u00e9rez V (2010) A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol 25:349\u2013355","journal-title":"Int Clin Psychopharmacol"},{"key":"6431_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/08039480500320025","volume":"59","author":"M Pompili","year":"2005","unstructured":"Pompili M, Girardi P, Ruberto A, Tatarelli R (2005) Suicide in borderline personality disorder: a meta-analysis. Nord J Psychiatry 59:319\u2013324","journal-title":"Nord J Psychiatry"},{"key":"6431_CR48","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/13651501.2019.1576904","volume":"23","author":"F Riffer","year":"2019","unstructured":"Riffer F, Farkas M, Streibl L, Kaiser E, Sprung M (2019) Psychopharmacological treatment of patients with borderline personality disorder: comparing data from routine clinical care with recommended guidelines. Int J Psychiatry Clin Pract 23:178\u2013188","journal-title":"Int J Psychiatry Clin Pract"},{"key":"6431_CR49","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1521\/pedi_2017_31_328","volume":"32","author":"C Rohde","year":"2018","unstructured":"Rohde C, Polcwiartek C, Correll CU, Nielsen J (2018) Real-world effectiveness of clozapine for borderline personality disorder: results from a 2-year mirror-image study. J Pers Disord 32:823\u2013837","journal-title":"J Pers Disord"},{"key":"6431_CR50","first-page":"40","volume":"24","author":"E Rutledge","year":"2007","unstructured":"Rutledge E, O'Regan M, Mohan D (2007) Borderline personality disorder and clozapine. I J Psychol Med 24:40\u201341","journal-title":"I J Psychol Med"},{"key":"6431_CR51","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/schbul\/17.2.247","volume":"17","author":"A Safferman","year":"1991","unstructured":"Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B (1991) Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 17:247\u2013261","journal-title":"Schizophr Bull"},{"key":"6431_CR52","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/0010-440X(81)90001-8","volume":"22","author":"PH Soloff","year":"1981","unstructured":"Soloff PH (1981) Pharmacotherapy of borderline disorders. Compr Psychiatry 22:535\u2013543","journal-title":"Compr Psychiatry"},{"key":"6431_CR53","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1055\/s-2007-979555","volume":"29","author":"T Steinert","year":"1996","unstructured":"Steinert T, Schmidt-Michel P-O, Kaschka W (1996) Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type under treatment with clozapine. Pharmacopsychiatry 29:111\u2013114","journal-title":"Pharmacopsychiatry"},{"key":"6431_CR54","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Br Med J 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"Br Med J"},{"key":"6431_CR55","doi-asserted-by":"publisher","unstructured":"Stoffers J, V\u00f6llm BA, R\u00fccker G, Timmer A, Huband N, Lieb K (2010) Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev 16(6):CD005653. https:\/\/doi.org\/10.1002\/14651858.CD005653.pub2","DOI":"10.1002\/14651858.CD005653.pub2"},{"key":"6431_CR56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11920-019-1126-9","volume":"22","author":"J Stoffers-Winterling","year":"2020","unstructured":"Stoffers-Winterling J, Storeb\u00f8 OJ, Lieb K (2020) Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Re 22:1\u201310","journal-title":"Curr Psychiatry Re"},{"key":"6431_CR57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1017\/S1092852915000784","volume":"21","author":"K Stone-Brown","year":"2016","unstructured":"Stone-Brown K, Naji M, Francioni A, Myers K, Samarendra H, Mushtaq-Chaudhry H, Heslop S, Sengupta S, Ross CC, Larkin F (2016) Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital. CNS Spectr 21:60\u201369","journal-title":"CNS Spectr"},{"key":"6431_CR58","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1080\/09585180110091994","volume":"12","author":"M Swinton","year":"2001","unstructured":"Swinton M (2001) Clozapine in severe borderline personality disorder. J Forens Psychiatry 12:580\u2013591","journal-title":"J Forens Psychiatry"},{"key":"6431_CR59","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4103\/0019-5545.70989","volume":"52","author":"AK Vohra","year":"2010","unstructured":"Vohra AK (2010) Treatment of severe borderline personality disorder with clozapine. Indian J Psychiatry 52:267\u2013269","journal-title":"Indian J Psychiatry"},{"key":"6431_CR60","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1080\/14789949.2017.1319969","volume":"28","author":"O White","year":"2017","unstructured":"White O, Hill SA, Coleman R, Delmage E (2017) Effect of clozapine on rates of risk incidents and functioning in female adolescents with a diagnosis of severe emerging emotionally unstable personality disorder. J Foren Psychiatry Psychol 28:737\u2013752","journal-title":"J Foren Psychiatry Psychol"},{"key":"6431_CR61","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/MOH.0000000000000391","volume":"25","author":"M Wici\u0144ski","year":"2018","unstructured":"Wici\u0144ski M, W\u0119clewicz MM (2018) Clozapine-induced agranulocytosis\/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol 25:22\u201328","journal-title":"Curr Opin Hematol"},{"key":"6431_CR62","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S2215-0366(16)30030-X","volume":"3","author":"G Zalsman","year":"2016","unstructured":"Zalsman G, Hawton K, Wasserman D, van Heeringen K, Arensman E, Sarchiapone M, Carli V, H\u00f6schl C, Barzilay R, Balazs J (2016) Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry 3:646\u2013659","journal-title":"Lancet Psychiatry"},{"key":"6431_CR63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1521\/pedi.17.3.233.22147","volume":"17","author":"MC Zanarini","year":"2003","unstructured":"Zanarini MC (2003) Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 17:233","journal-title":"J Pers Disord"},{"key":"6431_CR64","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/2045125313484323","volume":"3","author":"T Zarzar","year":"2013","unstructured":"Zarzar T, McEvoy J (2013) Clozapine for self-injurious behavior in individuals with borderline personality disorder. Ther Adv Psychopharmacol 3:272\u2013274","journal-title":"Ther Adv Psychopharmacol"},{"key":"6431_CR65","first-page":"61","volume":"47","author":"TR Zarzar","year":"2019","unstructured":"Zarzar TR, Catlett TL, O\u2019Connell MG, Harrelson BH, Wilson VP, Rashad GN, Morris DB, Williams JB, Peebles SS, Sheitman BB (2019) Clozapine reduces self-injurious behavior in a state prison population. J Am Acad Psychiatry Law 47:61\u201367","journal-title":"J Am Acad Psychiatry Law"},{"issue":"00","key":"6431_CR66","first-page":"21m1423","volume":"83","author":"S Zheng","year":"2022","unstructured":"Zheng S, Lee J, Chan SKW (2022) Utility and barriers to clozapine use: a joint study of Clinician\u2019s attitudes from Singapore and Hong Kong. J Clin Psychiatry 83(00):21m1423","journal-title":"J Clin Psychiatry"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-023-06431-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-023-06431-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T03:02:53Z","timestamp":1695006173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-023-06431-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["6431"],"URL":"https:\/\/doi.org\/10.1007\/s00213-023-06431-6","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"13 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}